In the last phase of cancer immuno-editing (i.e., “escape” phase), cancer cells produce large amounts of “pro-tolerogenic” kynurenine catalyzed by indoleamine 2,3-dioxygenase (IDO) processing of tryptophan [47]. The gene discussed is IDO2; the disease is cancer.